Canada markets open in 3 hours 36 minutes

IMV Inc. (IMV.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.12000.0000 (0.00%)
At close: 03:59PM EDT
Full screen
Previous Close1.1200
Open1.1300
Bid0.7000 x 0
Ask0.7000 x 0
Day's Range1.0700 - 1.1300
52 Week Range0.6200 - 9.0000
Volume15,761
Avg. Volume0
Market Cap13.117M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateSept 26, 2023 - Sept 30, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.40
  • Business Wire

    IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets

    DARTMOUTH, Nova Scotia, September 01, 2023--IMV Inc. (the "Company" or "IMV") announces today that it has accepted an offer (the "Offer") from IMV’s largest secured creditors (the "Secured Lenders"), pursuant to which IMV and its subsidiary, Immunovaccine Technologies Inc. have agreed to sell to the Secured Lenders its intellectual property assets (the "Transaction") in consideration for a partial reduction of debt owing to the Secured Lenders.

  • Business Wire

    IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process

    DARTMOUTH, Nova Scotia, July 26, 2023--IMV Inc. (the "Company" or "IMV"), recently announced an update on the Sales and Investment Solicitation Process (the "SISP") implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the "CCAA").

  • Business Wire

    IMV Receives NASDAQ Delisting Notice

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 08, 2023--IMV Inc. (the "Company" or "IMV") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exerci